

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/786,720	02/26/2004	Margot Mary O'Toole	WYE-030	2740
	7590 09/25/200 K & LOCKHART PRE	EXAMINER		
(FORMERLY KIRKPATRICK&LOCKHART NICHOLSON GRAHAM) STATE STREET FINANCIAL CENTER			MYERS, CARLA J	
ONE LINCOL		EK	ART UNIT	PAPER NUMBER
BOSTON, MA	02111-2950		1634	
			, MAIL DATE	DELIVERY MODE
			09/25/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
Office Action Comments	10/786,720	O'TOOLE ET AL.
Office Action Summary	Examiner	Art Unit
	Carla Myers	1634
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the o	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tir 17 apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D. (35 U.S.C. \$ 133)
Status		
1)⊠ Responsive to communication(s) filed on 01 Au	iaust 2007	
	action is non-final.	
3) Since this application is in condition for allowan		esecution as to the merits is
closed in accordance with the practice under E		
Disposition of Claims	,	
4)⊠ Claim(s) <u>20</u> is/are pending in the application.		
4a) Of the above claim(s) is/are withdraw	in from consideration	
5) Claim(s) is/are allowed.	m nom consideration.	
6)⊠ Claim(s) <u>20</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and/or	election requirement	
are subject to restriction and/or	election requirement.	
Application Papers		
9) The specification is objected to by the Examiner	•	
10) The drawing(s) filed on is/are: a) □ acce	pted or b) objected to by the I	Examiner.
Applicant may not request that any objection to the o	rawing(s) be held in abeyance. See	e 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction	on is required if the drawing(s) is ob	jected to. See 37 CFR 1.121(d).
11)☐ The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a a) All b) Some * c) None of:	priority under 35 U.S.C. § 119(a)	n-(d) or (f).
 Certified copies of the priority documents 	have been received.	
Certified copies of the priority documents	have been received in Applicati	on No
Copies of the certified copies of the priori	ty documents have been receive	ed in this National Stage
application from the International Bureau	(PCT Rule 17.2(a)).	
* See the attached detailed Office action for a list of	of the certified copies not receive	d.
Attachment(s)		
Notice of References Cited (PTO-892)	4) Interview Summary	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da 5) Notice of Informal P	
B) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	6) 🗓 Other: <u>Seque</u>	nce alyment
	·	- 04/10/0

Application/Control Number: 10/786,720

Art Unit: 1634

DETAILED ACTION

Page 2

Continued Examination Under 37 CFR 1.114

- 1. A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on August 1, 2007 has been entered.
- 2. Claim 20 is pending. All previous grounds of rejection are withdrawn in view of the amendments to claim 20. However, this action contains a new grounds of rejection as set forth below.

New Grounds of Rejection

Claim Rejections - 35 USC § 112 - New Matter

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 20 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Art Unit: 1634

The specification as originally filed does not appear to provide support for the amendment to claim 20 to recite a method comprising the step of comparing the expression of "SFRP1 (SEQ ID NO: 15) mRNA" in kidney samples of a mouse before and after administration of an agent to determine if said agent modulates expression of SEQ ID NO: 15 in the mouse. As broadly written, the claims encompass methods in which a mRNA consisting of or comprising SEQ ID NO: 15 is detected in a mouse. However, upon further review of the specification, it appears that SEQ ID NO: 15 constitutes the human SFRP1 mRNA. The mouse SFRP1 mRNA shares only 26.8% identity with SEQ ID NO: 15 and thereby is substantially distinct from the human SFRP1 mRNA of SEQ ID NO: 15 (see the attached sequence alignment). The specification does not teach the concept of detecting the human mRNA of SEQ ID NO: 15 in mice having lupus. For example, the specification does not teach the generation of transgenic mice expressing SEQ ID NO: 15 and the analysis of expression of SEQ ID NO: 15 in such transgenic mice to determine if an agent effects the expression of SEQ ID NO: 15. The specification (e.g., para [0077]) does teach that the "discovery of the LRG expression patterns in SLE/LN-affected animals allows for the screening of agents that can modulates LRG expression or LRG activity. The agents may be screened by their effects on LRG expression at the mRNA or protein level, or by their effect on the activity of the LRG product. "However, the specification exemplifies only methods in which the expression levels of mouse mRNAs are analyzed in SLE-affected mice using an Affymetrix gene chip array (pages 65-66). Human orthologs of mouse genes differentially expressed in SLE-affected mice were identified using HomoloGene (page

Art Unit: 1634

69). The specification (pages 18, 19, 21 and Table 1) indicates that the methods which detect lupus-related genes (LRGs) are intended to include the detection of mutants, isoforms and alternatively spliced variants of the LRGs. However, the specification does not appear to provide a sequence of the mouse SFRP1 mRNA that is overexpressed in SLE-affected mice. Accordingly, it does not appear that the specification as originally filed provides basis for the particular embodiment of a method of administering an agent to a mouse with lupus and comparing the expression of a mRNA comprising SEQ ID NO: 15 before and after said administration in order to determine if the agent modulates expression of SEQ ID NO: 15 in the mouse.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is 571-272-0747. The examiner can normally be reached on Monday-Thursday (6:30-5:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/786,720

Art Unit: 1634

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 5

/Carla Myers/

Primary Examiner, Art Unit 1634

```
<!--StartFragment-->BC094662
LOCUS
            BC094662
                                     4375 bp
                                                 mRNA
                                                         linear
                                                                  ROD 11-AUG-2006
DEFINITION Mus musculus secreted frizzled-related sequence protein 1, mRNA
             (cDNA clone MGC:102081 IMAGE:30363219), complete cds.
ACCESSION
             BC094662
            BC094662.1 GI:63102234
VERSION
KEYWORDS
            MGC.
SOURCE
            Mus musculus (house mouse)
  ORGANISM Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
             Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE
                (bases 1 to 4375)
  AUTHORS
            Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
            Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
            Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
            Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
            Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
            Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
            Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,
            Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
            Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,
            McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
            Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
            Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
            Fahey, J., Helton, E., Ketteman, M., Madan, A., Rodrigues, S.,
            Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,
            Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
            Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
            Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smailus, D.E.,
            Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.
  CONSRTM
            Mammalian Gene Collection Program Team
  TITLE
            Generation and initial analysis of more than 15,000 full-length
            human and mouse cDNA sequences
  JOURNAL
            Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
   PUBMED
            12477932
REFERENCE
            2
               (bases 1 to 4375)
  CONSRTM
           NIH MGC Project
  TITLE
            Direct Submission
  JOURNAL
            Submitted (06-MAY-2005) National Institutes of Health, Mammalian
            Gene Collection (MGC), Bethesda, MD 20892-2590, USA
            NIH-MGC Project URL: http://mgc.nci.nih.gov
  REMARK
            Contact: MGC help desk
COMMENT
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Dr. Jim Lin, University of Iowa
            cDNA Library Preparation: M. Bento Soares, University of Iowa
            cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
            DNA Sequencing by: Sequencing Group at the Stanford Human Genome
            Center, Stanford University School of Medicine, Stanford, CA 94305
            Web site:
                             http://www-shgc.stanford.edu
            Contact: (Dickson, Mark) mcd@paxil.stanford.edu
            Dickson, M., Schmutz, J., Grimwood, J., Rodriquez, A., and Myers,
            R. M.
            Clone distribution: MGC clone distribution information can be found
            through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
            Series: IRAK Plate: 195 Row: 1 Column: 16
            This clone was selected for full length sequencing because it
            passed the following selection criteria: matched mRNA gi: 7305480.
FEATURES
                     Location/Qualifiers
                     1. .4375
     source
```

```
/organism="Mus musculus"
                /mol type="mRNA"
                /strain="C57BL/6"
                /db xref="taxon:10090"
                /clone="MGC:102081 IMAGE:30363219"
                /tissue_type="Brain, mouse, 13.5,14.5,16.5,17.5 dpc"
                /clone lib="NIH BMAP FYO"
                /lab host="DH10B"
                /note="Vector: pYX-ASC"
   gene
               1. .4375
               /gene="Sfrp1"
                /note="synonym: sFRP-1"
                /db xref="GeneID:20377"
                /db xref="MGI:892014"
   CDS
               268. .1212
               /gene="Sfrp1"
               /codon start=1
               /product="secreted frizzled-related sequence protein 1"
               /protein id="AAH94662.1"
               /db xref="GI:63102235"
               /db xref="GeneID:20377"
               /db_xref="MGI:892014"
               /translation="MGVGRSARGRGGAASGVLLALAAALLAAGSASEYDYVSFQSDIG
               SYQSGRFYTKPPQCVDIPVDLRLCHNVGYKKMVLPNLLEHETMAEVKOOASSWVPLLN
               KNCHMGTQVFLCSLFAPVCLDRPIYPCRWLCEAVRDSCEPVMQFFGFYWPEMLKCDKF
               PEGDVCIAMTPPNTTEASKPQGTTVCPPCDNELKSEAIIEHLCASEFALRMKIKEVKK
               ENGDKKIVPKKKKPLKLGPIKKKELKRLVLFLKNGADCPCHQLDNLSHNFLIMGRKVK
               SQYLLTAIHKWDKKNKEFKNFMKRMKNHECPTFOSVFK"
ORIGIN
 Query Match
                   26.8%; Score 1196.8; DB 6; Length 4375;
 Best Local Similarity 62.0%; Pred. No. 0;
 Matches 2789; Conservative
                        0; Mismatches 1497; Indels 214; Gaps
        38 CCCGCGCCTTCCTGCTCGCCGCACCTCCGGGAGCCGGGGCGCACCCAGCCCGCAGCGCCG 97
          11111
                                       11 | | |
                                               -1
                                                    1
        98 CCTCCCGCCGCGCCGCCTCCGACCGCAGGCCGAGGGCCGCCACTGGCCGGGGGGGACCG 157
               1 11 1
                                    1 1
                                         11
                                           158 GGCAGCAGCTTGCGGCCGGGAGCCGGGCAACGCTGGGGACTGCGCCTTTTGTCCCCGGA 217
          139 GGGAGCAGCGCGAGCCGAGCCGGACCGGACCGGCACTGCGCC-TTTGTCCCCGGA 197
       198 GGCTCCGGGAAGTTTGCAGCGGGACGCGCGTGAAGGCAGCGTGGGCAGCCCCGACGTC 257
       ---CAACATGGGCGTCGGGGCGCAGCGCGGGGGTCGCGGCGG 302
       338 G---GCCCTGGGCGTGCTGCTGGCGCTGGGCGCGCTTCTGGCCGTGGGCTCGGCCAG 394
             303 GGCCGCCTCGGGAGTGCTGCTGGCGTTGGCCGCCGCTCTGCTGGCCGCGGGTTCGGCCAG 362
       395 CGAGTACGACTACGTGAGCTTCCAGTCGGACATCGGCCCGTACCAGAGCGGGCGCTTCTA 454
          363 CGAGTACGACTACGTGAGCTTCCAGTCCGACATCGGCTCGTATCAGAGCGGGCGCTTCTA 422
```

Qу

Db

ДУ		CACCAAGCCACCTCAGTGCGTGGACATCCCCGCGGACCTGCGGCTGTGCCACAACGTGGG	
Db		CACCAAGCCCCGCAGTGCGTGGACATCCCGGTGGACCTGAGGCTGTGCCACAACGTGGG	
Qу		CTACAAGAAGATGGTGCTGCCCAACCTGCTGGAGCACGAGACCATGGCGGAGGTGAAGCA	
Db	483	CTACAAGAAGATGGTGCTGCCCAACCTGCTGGAGCACGAGACCATGGCAGAGGTGAAGCA	542
QУ	575	GCAGGCCAGCTGGGTGCCCCTGCTCAACAAGAACTGCCACGCCGGGACCCAGGTCTT	634
Db	543	GCAGGCCAGCTGGTGCCGCTGCTCAACAAGAACTGCCACATGGGCACCCAGGTCTT	602
Qу	635	CCTCTGCTCGCTCTCGCGCCCGTCTGCCTGGACCGGCCCATCTACCCGTGTCGCTGGCT	694
Db	603	CCTCTGTTCGCCTCTGTCTGGACCGGCCCATCTACCCGTGTCGCTGGCT	662
Qу	695	CTGCGAGGCCGTGCGCGACTCGTGCGAGCCGGTCATGCAGTTCTTCGGCTTCTACTGGCC	754
Db	663	CTGCGAGGCCGTGCGCGACTCGTGCGAGCCGGTCATGCAGTTCTTCGGCTTCTACTGGCC	722
Qу	755	CGAGATGCTTAAGTGTGACAAGTTCCCGGAGGGGGACGTCTGCATCGCCATGACGCCGCC	814
Db	723		782
Qу	815	CAATGCCACCGAAGCCTCCAAGCCCCAAGGCACAACGGTGTGTCCTCCCTGTGACAACGA	874
Db	783		842
Qу	875	GTTGAAATCTGAGGCCATCATTGAACATCTCTGTGCCAGCGAGTTTGCACTGAGGATGAA	934
Db	843		902
Qу	935	AATAAAAGAAGTGAAAAAAGAAAATGGCGACAAGAAGATTGTCCCCAAGAAGAAGAAGCC	994
Db	903		962
Qу	995	CCTGAAGTTGGGGCCCATCAAGAAGAAGACCTGAAGAAGCTTGTGCTGTACCTGAAGAA	1054
Db	963		1022
Qу	1055	TGGGGCTGACTGTCCCTGCCACCAGCTGGACAACCTCAGCCACCACTTCCTCATCATGGG	1114
Db	1023		1082
Qу	1115	CCGCAAGGTGAAGAGCCAGTACTTGCTGACGGCCATCCACAAGTGGGACAAGAAAAACAA	1174
Db	1083		1142
Qy	1175	GGAGTTCAAAAACTTCATGAAGAAAATGAAAAACCATGAGTGCCCCACCTTTCAGTCCGT	1234
Db	1143		1202
Qу	1235	GTTTAAGTGATTCTCCCGGGGGCAGGGTGGGGAGCCTCGGGTGGGGTGGGAGCGGG	1294
Db	1203		1262
Qу	1295	GGGGACAGTG-CCCGGGAACCCGTGGTCACACACACGCACTGCCCTGTCAGTAGTGG	1350
Db	1263		1322

Qу	1351	ACATTGTAATCCAGTCGGCT-TGTTCTTGCAGCATTCCCGCTCCCTTTCCCTCCATAGCC	1409
Db	1323	CTTTTGCATTGCACCTGGCTCTGTTCCTACAGCGAACCCTCTCCCTTCCCTCCATAGCCA	1382
QУ	1410	ACGCTCCAAACCCCAGGGTAGCCATGGCCGGGTAAAGCAAGGGCCATTTAGATTAGGAAG	1469
Db	1383	CATCCAGCTAAGGCCACGGCCCTTTAGATTAGGAAGGCTTTTTTTT	1442
QУ	1470	GTTTTTAAGATCCGCAATGTGGAGCAGCCACTGCACAGGAGGAGGT	1518
Db	1443	CAGCAGGCCAGCAGGCACGGTGCAAAAGGAGAGGCAGAATCCTTTCACTGAGCCTCGGG	1502
QУ	1519	GACAAACCATTTCCAACAGCAACACAGCCACTAAAACACAAAAAGGGGGATTGGGCGGAA	1578
Db	1503	CACAAAAACAGAAAATGTTGGCCGGTTTGGAAAAACAAAACAAAACGGATTGTAAAGAA	1562
Qу	1579	AGTGAGAGCCAGCAGCAAAAACTACATTTTGCAACTTGTTGGTGTGGATCTATTGGC	1635
Db	1563	CTGCAGACGGACAGCTGCTCAACGTTGTTCGGGACATCATTACCAATTGCTTGTG	1622
QУ	1636	TGATCTATGCCT-TTCAACTAGAAAATTCTAATGATTGGCAAGTCACGTTGTTTTCAGGT	1694
Db	1623		1682
Qy	1695	CCAGAGTAGTTTCTTTCTGTCTGCTTTAAATGGA-AACAGACTCATACCACACTTACAAT	1753
Db	1683		1742
Qу	1754	TAAGGTCAAGCCCAGAAAGTGATAAGTGCAGGGAGGAAAAGTGCAAGTCCATTATCTAAT	1813
Db	1743	CA	1802
Qу	1814	AGTGACAGCAAAGGGACCAGGGGAGAGGCATTGCCTTCTCTGCCCACAGTCTTTCCGTGT	1873
Db	1803	CAGGGTATCCCAGTATAGAACGGGATAGCTAAGGGTTTGGGTGGG	1862
Qу	1874	GATTGTCTTTGAATCTGAATCAGCCAGTCTCAGATGCCCCAAAGTTTCGGTTCCTATGAG	1933
Db	1863	CTACCTTCAGCTTTTGAACTGGCCACCTTTGATAGGAAACTGTAGGT	1909
Qу	1934	CCCGGGGCATGATCTGATCCCCAAGACATGTGGAGGGGCAGCCTGTGCCTTTGTGT	1993
Db	1910	CTCAGATGGACACTTCTACCAGTCCATCGGGATACAAGGATGCCAGGCAAGGGTCTGCTT	1969
Qу	1994	CAGAAAAAGGAAACCACAGTGAGCCTGAGAGAGACGGCGATTTTCGGGCTGAGAAGGCAG	2053
Db	1970		2029
Qу	2054	TAGTTTTCAAAACACATAGTTAAAAAAGAAACAAATGAAAAAATTTTAGAACAGTCCAG	2113
Db	2030	CAGCTACTAGTTŢTCAACAATAGAGTGGAAGAAATGAGCAAAGGTAGAAATGTCAAG	2086
Qу	2114	CAAATTGCTAGTCAGGGTGAATTGTGAAATTGGGTGAAGAGCTTAGGATTCTAATCTCAT	2173
Db	2087		2146
Qy	2174	GTTTTTCCTTTTCACATTTTTAAAAGAACAATGACAAACACCCACTTATTTTTC	2228
Db	2147		2206
Qy	2229	AAGGTTTTA-AAACAGTCTACATTGAGCATTTGAAAGGTGTGCTAGAACAAGGTCTCCTG	2287

2207 AAGGCTTGAGTAAAAGTCCACACTCAGCATTTCAAAGACTAAC------GTCGTT 2255 Db 2288 ATCCGTCCGAGGCTGCTTCCCAGAGGAGCAGCTCTCCCCAGGCATTTGCCAAGGGAGGCG 2347 Qу 2256 GACTGCCCAAGGCTGCCCTCTTAATACACCG----CCTATGCATGTGCTGTGGAAGGC- 2309 Db 2348 GATTTCCCTGGTAGTGTAGCTGTGTGGCTTTCCTTCCTGAAGAGTCCGTGGTTGCCCTAG 2407 Qу 1 11 11 Db 2310 -AACTCTGTGCATGTGCTGTGGAGGAGATGGGCCTCATG-GCTGTGCCTGGCTGCCCAGG 2367 Qу Db 2368 AATCAGTATAGCTGTGGAAGGAGACAGTATCCATAGACTCTGCTTTTCTGCAAGGAA-AG 2426 Qу 1 Db Qу Db 2487 AGCCCTCC-----ACCTTTACTTTTGCATTCCTCCGGTCATATTCTTTTGAGGCTA 2537 Qу 2588 GTGTCCCCATCCAGCGAGAGAGTTTCAAAAGCAAAACATCTCTGCAGTTTTTCCCAAGTA 2647 Db 2648 CCCTGAGATACTTCCCAAAGCCCTTATGTTTAATCAGCGATGTATATAAGCCAGTTCACT 2707 Qу Db 2597 CCCAGAGGTATTTCTCAAAGTTGGTATGCTTAATAAGTGATGTAAATATTCCAGTTCTCT 2656 Qу 1.11 11 1 1111 1 1 111111 Db Qу 2768 AATTTCTTCCCCCAAAGCCGGATTCTTAATTCTCTGCAACACTTTGAGGACATTTATGAT 2827 2708 AATTTCTTCCACCAAAGTCTGA----TAATTCCCCACCGCATCCATGGGGCTACAGTGAC 2763 Db 2828 TGTCCCTCTGGGCCAATGCTTATACCCAGTGAGGATGCTGCAGTGAGGCTGTAAAGTGGC 2887 Qу 2764 TGTCCCTTTGG-----CATACTCAATCCAGAGGTAGGAATGATTTTGAAGAAT--C 2812 Db 2888 CCCCTGCGGCCCTAGCCTGACCCGGAGAAAGGATGGTAGATTCTGTTAACTCTTGAAGAC 2947 Qу Db 2813 ATCTAGTGGCCTTGGATTGACCCAGAAACAGGAA---AACTCTGGTTACTTCTGAAAGAC 2869 2948 TCCAGTATGAAAA-TCAGCATGCCCGCCTAGTTACCTACCGGAGAGTTATCCTGATAAAT 3006 Qу Db 2870 TCCAGCCTGAAAACTCACCATGCCAACTTAGTTACTGACCTGAGTGGGGTAGTGACCTAA 2929 3007 TAACCTCTCACAGTTAGTGATCCTGTCCTTTTAACACCTTTTTTGTGGGGGTTCTCTCTGA 3066 Qу 2930 TTAACT-TCATGTTTAGTAGTCCTATTATCTTAACCC----TTTTAAGAATACTTCCAA 2983 Db 3067 CCTTTCATCGTAAAGTGCTGGGGACCTTAAGTGATTTGCCTGTAATTTTGGATGATTAAA 3126 Qу Db 2984 CCTTAATCACAATGTTATGAGGAACCTTAGGTGATTTGCCTATCATTGTGGATGATTTAA 3043 3127 AAATGTGTATATATTAGCTAATTAGAAATATTCTACTTCTCTGTTGTCAAACTGAAAT 3186 Qу

Db	3044	AAATATGTATGTGCATTAG-TAATTAGAAATAGTCTAACCTCATTGTCCATAACTGAAAT	3102
Qу	3187	TCAGAGCAAGTTCCTGAGTGCGTGGATCTGGGTCTTAGTTCTGGTTGATTCACTCAAGAG	3246
Db	3103		3159
Qу	3247	TTCAGTGCTCATACGTATCTGCTCATTTTGACAAAGTGCCTCATGCAACCGGGCCCTCTC	3306
Db	3160		3210
Qy	3307	TCTGCGGCAGAGTCCTTAGTGGAGGGGTTTACCTGGAACATAAGTA-GTTACCACAGAAT	3365
Db ·	3211		3270
Qу	3366	ACGGAAGAGCAGGTGACTGTGCTGCAGCTCTCTAAATGGGAATTCTCAGGTAGGAAGC	3425
Db	3271	CAGCATAAAAGGGAGGACATGTTCTGGGGGGGCTCCAGATTGGGAACCCTCAGGAAGT	3327
Qу	3426	AACAGCTTCAGAAAGAGCTCAAAATAAATTGGAAATGTGAATCGCAGCTGTGGGTTTTAC	3485
Db	3328		3387
Qy .	3486	CACCGTCTGTCTCAGAGTCCCAGGACCTTGAGTGTCATTAGTTACTTTATTG	3537
Db	3388		3447
Qу	3538	AAGGTTTTAGACCCATAGCAGCTTTGTCTCTGTCACATCAGCAATT	3583
Db	3448	GATTTCAGACACACACACACACACACACACACACACACAC	3507
Qу	3584	TCAGAACCAAAAGGGAGGCTCTCTGTAGGCACAGAGCTGCACTATCACGAGCCTTTGTTT	3643
Db	3508		3567
Qу	3644	TTCTCCACAAAGTATCTAACAAAACCAATGTGCAGACTGATTGGCCTGGTCATTGGTCTC	3703
Db	3568		3626
Qу	3704	CGAGAGAGGAGGTTTGCCTGTGATTTGCCTGTGATTTCCTAATTATCGCTAGGGCCAAGG	3763
Db	3627		3675
Qу	3764	TGGGATTTGTAAAGCTTTACAATAATCATTCTGGATAGAGTCCTGGGAGGTCCTTGGCAG	3823
Db	3676	TCAGATTTGGAAAGCTTTAAAATAGTCATTCCGGAGAGTCAGGGAAAGCT	3725
Qу	3824	AACTCAGTTAAATCTTTGAAGAATATTTGTAGTTATCTTAGAAGATAGCATGGGAGGTGA	3883
Db	3726		3785
Qу	3884	GGATTCCAAAAACATTTTATTTTTAAAATATCCTGTGTAACACTTGGCTCTTGGTACCTG	3943
Db	3786		3845
Qy	3944	TGGGTTAGCATCAAGTTCTCCCCAGGGTAGAATTCAATCAGAGCTCCAGTTTGCATTTGG	4003
Db	3846	TGGGTTAGCACTAGGTCCTCCCTGGGGCTGAGTCTAAGCCCAGTTCCAGGCTTCCTAAGA	3905
Ωу	4004	ATGTGTAAATTACAGTAATCCCATTTCCCAAACCTAAAATCTGTTTT-TCTCATCAGACT	4062
Ob	3906	ATGTGTAAATTACAGAAATCACATTTCCCAAAGCTAGAACCTGTTTTATCTTGTTAGCCT	3965

4063 CTGAGTAACTGGTTGCTGTCATAACTTCATAGATGCAGGAGGCTCAGGTGATCTGTTT 4122 Qу Db 3966 CCCTGTAACCAGATGCTCTGTTGGACCTTCATAGCCGGACGTGGTTCA--AGATGTGCTC 4023 4123 GAGGAGACCCCTAGGCAGCCTGCAGGGAATAACATACTGGCCGTTCTGACCTGTTGCC 4182 Qу 1111 11 1 1 Db 4024 CAGAAGCAGACCCGGGGTCACATCTCCAGGATGGCATGTTGGCTGCTCTGACCTGGCG-C 4082 4183 AGCAGATACACAGGACATGGATGAAATTCCCGTTTCCTCTAGTTTCTTCCTGTAGTACTC 4242 Qу 4083 TGTGGGTCCTAAGCGCAGAGACGGAATTCCTGTTGGCCCTGGTTCCCCCCTCCTCGCACC 4142 Db 4243 CTCT-----TTTAGATCCTAAGTCTCT--TACAAAAGCTTTGAATACTGTGAAA 4289 Qу Db 4143 CCCTGAGGACTCCACTTTATAGCCTAAGCCTTTTATACAAAAGCTTTGAATACTGTGAAG 4202 4290 ATGTTTTACATTCCATTTCATTTGTGTTGTTTTTTTAACTGCATTTTTACCAGATGTTTTG 4349 Qу Db 4203 ATGTTTTACATTCCTTCTCATTCCTGTTG-TTTCTTAACTACATTTGACCAGATGTTTTG 4261 4350 ATGTTATCGCTTATGTTAATAGTAATTCCCGTACGTGTTCATTTTATTTTCATGCTTTTT 4409 Qу 4262 ATGTTATCACGTATGTTAATAGTGATTCCCAGGTGTG----TTTTGTTTTCATGCTTTCC 4317 Db Qу <!--EndFragment-->